Elanco Animal Health IncNYSE:ELAN
- LAST PRICE12.9200
- TODAY'S CHANGE (%)-0.4700 (-3.5101%)
- Bid / Lots12.9100/ 5
- Ask / Lots12.9200/ 6
- Open / Previous Close13.3600 / 13.3900
- Day Range
- 52 Week Range
- Volume1,141,736
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ELAN |
|---|---|---|
| 09:32 ET | 15502 | 13.29 |
| 09:33 ET | 5619 | 13.29 |
| 09:35 ET | 3153 | 13.29 |
| 09:37 ET | 1109 | 13.31 |
| 09:39 ET | 1969 | 13.26 |
| 09:42 ET | 100467 | 13.24 |
| 09:44 ET | 7856 | 13.2425 |
| 09:46 ET | 3262 | 13.26 |
| 09:48 ET | 6028 | 13.205 |
| 09:50 ET | 8532 | 13.105 |
| 09:51 ET | 6179 | 13.105 |
| 09:53 ET | 11961 | 13.13 |
| 09:55 ET | 7081 | 13.065 |
| 09:57 ET | 8363 | 13.04 |
| 10:00 ET | 6062 | 13.04 |
| 10:02 ET | 17758 | 13.04 |
| 10:04 ET | 27736 | 13.035 |
| 10:06 ET | 15170 | 13.03 |
| 10:08 ET | 21855 | 13.035 |
| 10:09 ET | 14448 | 13.045 |
| 10:11 ET | 27333 | 12.995 |
| 10:13 ET | 191104 | 13.045 |
| 10:15 ET | 31886 | 13.055 |
| 10:18 ET | 19020 | 13.055 |
| 10:20 ET | 31436 | 13.055 |
| 10:22 ET | 18412 | 13.055 |
| 10:24 ET | 23512 | 13.005 |
| 10:26 ET | 329598 | 12.985 |
| 10:27 ET | 40548 | 12.96 |
| 10:29 ET | 16415 | 12.935 |
| 10:31 ET | 12350 | 12.9147 |
| 10:33 ET | 23344 | 12.92 |
Today
Shareholders of Elanco Animal Health Incorporated Should Contact Levi & Korsinsky Before December 6, 2024 to Discuss Your Rights - ELAN, from 1 hour ago by Dow Jones
1 hour ago by Dow JonesElanco (ELAN) Hit with Investor Lawsuit Over New Drug - Hagens Berman, from 1 hour ago by Dow Jones
1 hour ago by Dow JonesContact Levi & Korsinsky by December 6, 2024 Deadline to Join Class Action Against Elanco Animal Health Incorporated (ELAN), from 2 hours ago by Dow Jones
2 hours ago by Dow JonesELAN STOCK REPORT: Suffer Losses on Your Elanco Animal Health Investment? Contact BFA Law about the Pending Class Action Lawsuit (NYSE:ELAN), from 3 hours ago by Dow Jones
3 hours ago by Dow JonesLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 6, 2024 in Elanco Lawsuit - ELAN, from 3 hours ago by Dow Jones
3 hours ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Elanco Animal Health Inc | 6.6B | 31.6x | --- |
Halozyme Therapeutics Inc | 6.2B | 15.3x | --- |
Phibro Animal Health Corp | 961.6M | 55.4x | -46.35% |
Supernus Pharmaceuticals Inc | 2.0B | 33.7x | -59.02% |
Eagle Pharmaceuticals Inc | 12.3M | 0.9x | -4.75% |
Elite Pharmaceuticals Inc | 658.9M | -104.0x | --- |
Company Information
Elanco Animal Health Incorporated is an animal health company. The Company is focused on delivering products and services to prevent and treat disease in farm animals and pets. Its diverse, durable product portfolio serves animals across many species, primarily: dogs, cats and cattle, poultry, swine, and sheep. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio has products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, and poultry. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.
Contact Information
- Headquarters
- 2500 Innovation Way NGREENFIELD, IN, United States 46140-9163
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Lawrence Kurzius
- President, Chief Executive Officer, Director
- Jeffrey Simmons
- Chief Financial Officer, Executive Vice President
- Todd Young
- Executive Vice President, General Counsel, Company Secretary
- Shiv O'Neill
- Executive Vice President, Human Resources, Corporate Communications and Administration
- David Kinard
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.6B |
|---|---|
Revenue (TTM) | $4.5B |
Shares Outstanding | 494.4M |
Elanco Animal Health Inc does not pay a dividend. | |
Beta | 1.42 |
EPS | $0.41 |
Book Value | $12.63 |
P/E Ratio | 31.6x |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | 7.6x |
Operating Margin | 16.03% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
